CureGene Presents Two Preclinical Studies of CG-0416 at Obesity Week 2026
Summary
CG-0416 combined with a reduced-dose GLP-1 receptor agonist produced greater weight loss, and slower weight regain after the agonist was stopped
Description from Amherst Bee.
Who is covering this
-
CureGene Presents Two Preclinical Studies of CG-0416 at Obesity Week 2026
CG-0416 combined with a reduced-dose GLP-1 receptor agonist produced greater weight loss, and slower weight regain after the agonist was stopped
Comments
Comments need JavaScript.